This Article Full Text Full Text (PDF) All Versions of this Article: 92/1/117    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willemsen, R. H. Articles by Hokken-Koelega, A. C. Search for Related Content PubMed PubMed Citation Articles by Willemsen, R. H. Articles by Hokken-Koelega, A. C. Related Collections Cardiovascular Endocrinology Metabolism Pediatric Endocrinology

Effect of Growth Hormone Therapy on Serum Adiponectin and Resistin Levels in Short, Small-for-Gestational-Age Children and Associations with Cardiovascular Risk Parameters

Department of Pediatrics (R.H.W., M.v.D., A.C.H.-K.), Division of Endocrinology, Erasmus Medical Centre Sophia, 3015 GJ Rotterdam, The Netherlands; and Department of Internal Medicine (Y.B.d.R.), Diagnostic Laboratory Endocrinology, Department of Clinical Chemistry (Y.B.d.R., A.W.v.T.), University Medical Centre Rotterdam, and Department of Epidemiology and Biostatistics (P.G.M.), Erasmus Medical Centre, 3000 CA Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Ruben Willemsen, M.D., Erasmus Medical Center Sophia, Room SP-3435, Dr. Molenwaterplein 60, 3015 GJ Rotterdam, The Netherlands. E-mail: r.h.willemsen{at}erasmusmc.nl.

Background: Adiponectin and resistin are fat cell-derived hormones, which are thought to be respectively protective and disadvantageous with regard to the development of cardiovascular disease and diabetes mellitus type 2. Low birth weight has been associated with increased risks for the development of these diseases. In short, small-for-gestational-age (SGA) children, GH therapy has several positive effects regarding cardiovascular risk factors. On the other hand, concern has been expressed about the effects of GH therapy on insulin sensitivity.

Methods: We measured adiponectin and resistin levels in 136 short prepubertal children born SGA and their association with cardiovascular risk parameters and growth factors. Also, we compared the levels with normal-statured controls. The effect of GH treatment was evaluated in 50 short SGA children vs. baseline and vs. an untreated sex- and age-matched SGA control group.

Results: Short SGA children had similar adiponectin and lower resistin levels, compared with normal-statured controls. In GH-treated SGA children, neither adiponectin nor resistin levels changed significantly during 2 yr of GH treatment. Compared with untreated sex- and age-matched SGA controls, GH-treated SGA children had similar adiponectin and lower resistin levels. Adiponectin correlated inversely with age but not any cardiovascular risk parameter or growth factor. Higher IGF-I levels in GH-treated children were associated with lower resistin levels.

Conclusions: Compared with normal-statured controls, short prepubertal SGA children had similar adiponectin and lower resistin levels. Two years of GH treatment had no effect on their adiponectin and resistin levels.

This article has been cited by other articles:

				R. H. Willemsen, S. W. K. de Kort, D. C. M. van der Kaay, and A. C. S. Hokken-Koelega Independent Effects of Prematurity on Metabolic and Cardiovascular Risk Factors in Short Small-for-Gestational-Age Children J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 452 - 458. [Abstract] [Full Text] [PDF]

				S. Lin, E.-J. D. Lin, D. Boey, N. J. Lee, K. Slack, M. J. During, A. Sainsbury, and H. Herzog Fasting Inhibits the Growth and Reproductive Axes via Distinct Y2 and Y4 Receptor-Mediated Pathways Endocrinology, May 1, 2007; 148(5): 2056 - 2065. [Abstract] [Full Text] [PDF]